No prior authorization, no step therapy, and no formulary restrictions apply to PlexusDx compounds
Glucagon-like peptide 1 receptor agonists (GLP-1s) are on track to become one of the largest drug classes in history, driven by demand for weight loss alternatives and the potential of GLP-1s to treat a range of conditions such as diabetes, cardiovascular risk, liver disease, and dementia
Statins remain the gold-standard first-line treatment for elevated LDL cholesterol, capable of reducing LDL levels by 3050% depending on dose and agent
This is the profile with the cleanest mechanism case
Skin-whitening and skin-condition-improving effects of topical oxidized glutathione: a double-blind and placebo-controlled clinical trial in healthy women
Individuals with higher external eating scores at the start of the study tended to show greater weight loss